Statin drugs, which are commonly used by people for reducing their cholesterol and risk of heart disease, may prevent liver cancer and lead to a reduction in the need for gallbladder removals.
These findings are based on two studies published in the journal Gastroenterology, one of which has shown that statin use is associated with a significant reduction in the risk of hepatocellular carcinoma (HCC), or liver cancer, among diabetics.
"Our study provides the first indication of a cancer preventive effect for statins specific to HCC. While these findings need to be confirmed in future studies, we are hopeful that further research continues to show the beneficial effect of statins for liver cancer prevention in patients with diabetes," said Dr. Hashem B. El-Serag, of the Baylor College of Medicine and lead author of the study.
The researchers undertook an epidemiological study in a large cohort of diabetics, whose risk of HCC was higher than average, to characterize the relationship between statin use and HCC and other liver disease. They examined 1,303 cases and 5,212 controls; the mean age was 72 years.
According to the research team, 99 percent were men and 13 percent were African Americans. A significantly smaller proportion of cases (34.3 percent) had at least one filled prescription for statins than controls (53.1 percent), they said.
The study unveiled a significant inverse association between having statin prescriptions filled and the risk of developing HCC.